P. Y. Liu

Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer

David S. Alberts, P. Y. Liu, Edward V. Hannigan et al. · New England Journal of Medicine · 1996 · 1.2K citations · Full text

Medicine, Oncology, Surgery +5

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome

Jeffrey A. Sosman, Joseph M. Unger, P. Y. Liu et al. · Journal of Clinical Oncology · 2002 · 207 citations

Medicine, Immunology, Oncology +17

Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix

William A. Peters, P. Y. Liu, Rolland J. Barrett et al. · Obstetrical & Gynecological Survey · 2000 · 180 citations

Medicine, Oncology, Radiation Oncology +17

Evaluation of Amonafide in Cervical Cancer, Phase II

Vinay K. Malviya, P. Y. Liu, David S. Alberts et al. · American Journal of Clinical Oncology · 1992 · 59 citations

Medicine, Pharmacology, Pharmacotherapy +17

Phase III study of intraperitoneal cisplatin-intravenous cyclophosphamide versus intravenous cisplatin-intravenous cyclophosphamide in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG Intergroup study

David S. Alberts, P. Y. Liu, Edward V. Hannigan et al. · International Journal of Gynecological Cancer · 1996 · 30 citations

Medicine, Gynecology, Oncology +15